Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study

Trial Profile

Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Gastrointestinal haemorrhage; Oesophageal varices; Variceal haemorrhage
  • Focus Adverse reactions
  • Acronyms RFXM
  • Most Recent Events

    • 16 Aug 2017 Planned number of patients changed from 50 to 60.
    • 16 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
    • 16 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top